Cannabinoids acting on classical cannabinoid receptor sites (CB1 and CB2) and a variety of other cannabinoid-sensitive receptor sites (e.g., TRPV1, Peroxisome proliferator-activated receptor gamma—PPARγ, dopamine, glutamate, GABA) have demonstrated a considerable therapeutic impact by attenuating signs and symptoms such as inflammation, oxidative stress, pain, stress, movement disorders—tremors, rigidity, bradykinesia, L-DOPA-induced dyskinesia [77], mood disorders (e.g., depression), and insomnia [78]. The gene discussed is PPARG; the disease is insomnia measurement.